Amine compound and use thereof
    4.
    发明授权
    Amine compound and use thereof 有权
    胺化合物及其用途

    公开(公告)号:US07833991B2

    公开(公告)日:2010-11-16

    申请号:US11704860

    申请日:2007-02-09

    IPC分类号: C07D403/02 A01N43/50

    摘要: It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1): In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(═O) or NR11; and D is a group represented by the following general formula (4) or (6). In the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.

    摘要翻译: 旨在提供对HIV病毒感染,风湿病和癌症转移等疾病有效的新型胺化合物。 即,由以下通式(1)表示的胺化合物:在典型情况下,A1和A2各自表示任选取代的单环或多环芳族杂环; W表示环状C 3-10亚烷基,任选取代的单环或多环芳族杂环,单环或多环芳环或部分饱和多环芳环; X表示O,CH 2,C(= O)或NR 11; D为由以下通式(4)或(6)表示的基团。 在式(6)中,Q表示单键,S,O或NR 12; Y为由以下通式(7)表示的基团。 z表示任选取代的单环或多环芳环。 式(6)中,B表示NR25R26。 在上式中,R 1至R 26各自表示氢,烷基,烯基或炔基。

    Benzene derivatives and pharmaceutical composition
    10.
    发明授权
    Benzene derivatives and pharmaceutical composition 失效
    苯衍生物和药物组成

    公开(公告)号:US5696118A

    公开(公告)日:1997-12-09

    申请号:US457147

    申请日:1995-06-01

    摘要: A benzene derivative of the formula (I): ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -haloalkyl, --NH.sub.2, --NHR.sup.21 ; R.sup.2 is hydroxyl, --OR.sup.22, three- to seven-membered saturated cycloaliphatic amino optionally interrupted by one or more nitrogen, oxygen or sulfur atoms, --NHR.sup.23, --N(R.sup.24).sub.2, --NH.sub.2 ; R.sup.4 is hydrogen, C.sub.1-6 -alkyl, or --C(.dbd.O)R.sup.25 ; R.sup.7 is --CO--, --SO.sub.2 --; R.sup.8 is --CO--, single bond; R.sup.12 is --R.sup.11 --R.sup.5 ; R.sup.11 is --N(R.sup.5)--, --NH--, --O--, --N(R.sup.26)--, --N(C(.dbd.O)R.sup.27)--, --N(C(.dbd.O)NH.sub.2)--, --N(C(.dbd.O)NHR.sup.28)--; R.sup.13 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -haloalkyl, --NHC(.dbd.O)(CH.sub.2).sub.m C.sub.6 H.sub.5, --NHC(.dbd.O)R.sup.29, --NHC(.dbd.O)CH(C.sub.6 H.sub.5).sub.2, --NH.sub.2, --NHR.sup.30, --(CH.sub.2).sub.n C.sub.6 H.sub.5 ; Z is C, CH, N; A is CH, N; R.sup.5 is hydrogen, --CH.sub.2 C.sub.6 H.sub.4 COOH, --CH.sub.2 C.sub.6 H.sub.4 COOR.sup.31, --CH.sub.2 C.sub.6 H.sub.4 OH, --CH.sub.2 C.sub.6 H.sub.4 OR.sup.32, --CH.sub.2 C.sub.6 H.sub.4 NH.sub.2, --CH.sub.2 C.sub.6 H.sub.4 N(R.sup.33).sub.2, --CH.sub.2 C.sub.6 H.sub.4 -azole, --CH.sub.2 C.sub.6 H.sub.4 NHR.sup.34, --CH.sub.2 C.sub.6 H.sub.4 C.sub.6 H.sub.4 R.sup.14 ; R.sup.14 is azole, --COOH; R.sup.21 to R.sup.34 are independently C.sub.1-6 -alkyl or C.sub.1-6 -haloalkyl; m is 0 to 6; n is 0 to 6; t is 0 or 1, with the proviso that when Z is N, R.sup.5 is hydrogen, --CH.sub.2 C.sub.6 H.sub.4 COOH, --CH.sub.2 C.sub.6 H.sub.4 COOR.sup.31, --CH.sub.2 C.sub.6 H.sub.4 OH, --CH.sub.2 C.sub.6 H.sub.4 OR.sup.32, --CH.sub.2 C.sub.6 H.sub.4 NH.sub.2, --CH.sub.2 C.sub.6 H.sub.4 N(R.sup.33).sub.2, --CH.sub.2 C.sub.6 H.sub.4 -azole, or --CH.sub.2 C.sub.6 H.sub.4 NHR.sup.34, or a salt thereof, and a pharmaceutical composition comprising said benzene derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier are disclosed.

    摘要翻译: 式(I)的苯衍生物:其中R 1是氢,C 1-6 - 烷基,C 1-6 - 卤代烷基,-NH 2,-NHR 21; R2是羟基,-OR22,任选地被一个或多个氮,氧或硫原子间隔的三至七元饱和脂环族氨基,-NHR 23,-N(R 24)2,-NH 2; R 4是氢,C 1-6 - 烷基或-C(= O)R 25; R 7是-CO - , - SO 2 - ; R8是-CO-,单键; R12为-R11-R5; R 11是-N(R 5) - , - NH - , - O - , - N(R 26) - , - N(C(= O)R 27) - , - N(C(= O)NH 2) (C(= O)NHR 28) - ; R 13是氢,C 1-6 - 烷基,C 1-6 - 卤代烷基,-NHC(= O)(CH 2)m C 6 H 5,-NHC(= O)R 29,-NHC(= O)CH(C 6 H 5)2,-NH 2, -NHR 30, - (CH 2)n C 6 H 5; Z是C,CH,N; A是CH,N; R5是氢,-CH2C6H4COOH,-CH2C6H4COOR31,-CH2C6H4OH,-CH2C6H4OR32,-CH2C6H4NH2,-CH2C6H4N(R33)2,-CH2C6H4-唑,-CH2C6H4NHR34,-CH2C6H4C6H4R14; R14是唑,-COOH; R 21至R 34独立地为C 1-6 - 烷基或C 1-6 - 卤代烷基; m为0〜6; n为0〜6; t为0或1,条件是当Z为N时,R5为氢,-CH2C6H4COOH,-CH2C6H4COOR31,-CH2C6H4OH,-CH2C6H4OR32,-CH2C6H4NH2,-CH2C6H4N(R33)2,-CH2C6H4-唑或-CH2C6H4NHR34, 或其盐,以及包含所述苯衍生物或其药学上可接受的盐和药学上可接受的载体的药物组合物。